We, therefore, aimed to validate in vitro the role of EZH2 in CD38 expression and selected a panel of 8 HMCLs characterized by a low (JJN-3, XG-20, AMO-1, and XG-6), intermediate (L363, XG-19) and high (XG-7, XG-2) basal CD38 cell-surface expression, and representative of different MM molecular subgroups (XG-6; AMO-1; JJN-3; XG-20; L-363; XG-19; XG-7; XG-2) [11]. This evidence concerns the gene EZH2 and Miyoshi myopathy.